Key result
An 82-year-old woman developed a rare splenic artery thrombosis resulting in a large splenic infarct within 21 days of receiving her first dose of the ChAdOx1 nCov-19 vaccine.
Case Report (n=1)
This case report highlights a potential rare thromboembolic complication (splenic artery thrombosis) following the first dose of the ChAdOx1 nCov-19 vaccine.
May signal rare post-vaccine splenic infarction; hypothesis-generating and requires confirmation before clinical implications.
We present the case of an 82-year-old woman admitted to a regional emergency general surgery centre with severe left upper quadrant abdominal pain and tenderness within 21 days of receiving the first dose of the ChAdOx1 nCov-19 vaccine (Vaxzevria, AstraZeneca). Following further investigation through CT imaging, a thrombus was discovered in the patient's splenic artery resulting in a large splenic infarct. Splenic infarcts are rare and it is important to note the association between time of administration of the first dose of vaccine and the occurrence of thromboembolic complications in the noted absence of other risk factors for this condition. We hypothesise a link between Vaxzevria vaccine injection and a rare form of thromboembolic complication: thrombosis of the splenic artery.
No takes yet. Share an insight, caveat, or question.
Anderson et al. (2021) conducted a case report in Splenic infarction due to arterial thrombosis (n=1). ChAdOx1 nCov-19 vaccine (Vaxzevria, AstraZeneca) was evaluated on Splenic infarction due to arterial thrombosis. An 82-year-old woman developed a rare splenic artery thrombosis resulting in a large splenic infarct within 21 days of receiving her first dose of the ChAdOx1 nCov-19 vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: